Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma.
about
Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell linesGenetic and molecular abnormalities in tumors of the bone and soft tissues.Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology GroupWeighted Area Under the Receiver Operating Characteristic Curve and Its Application to Gene Selection.Ewing tumor: tumor biology and clinical applications.Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and ExpectationsEwing's sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities.Molecular genetics of pediatric soft tissue tumors: clinical application.Primary multidisciplinary management of extremity soft tissue sarcomas.Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours.Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2.Peripheral primitive neuroectodermal tumor of the cervical spine.Current concepts in the molecular genetics of pediatric brain tumors: implications for emerging therapies.Gene translocations in musculoskeletal neoplasms.Clinical relevance of molecular genetics to paediatric sarcomasEwing sarcoma: prognostic criteria, outcomes and future treatment.Molecular abnormalities in Ewing's sarcoma.Recent advances in the molecular pathology of soft tissue sarcoma: implications for diagnosis, patient prognosis, and molecular target therapy in the future.The insulin-like growth factor system and sarcomas.Development of IGF-IR Inhibitors in Pediatric Sarcomas.Insulin-like growth factor 1 receptor as a therapeutic target in ewing sarcoma: lack of consistent upregulation or recurrent mutation and a review of the clinical trial literature.Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage.Differential regulation of the response to DNA damage in Ewing's sarcoma cells by ETS1 and EWS/FLI-1.Desktop transcriptome sequencing from archival tissue to identify clinically relevant translocations.A mechanistic study on the metastasis inducing function of FUS-CHOP fusion protein in liposarcoma.Prognostic and therapeutic relevance of the IGF pathway in Ewing's sarcoma patients.The emerging role of insulin-like growth factor 1 receptor (IGF1r) in gastrointestinal stromal tumors (GISTs).Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program.EWS/FLI-1 oncoprotein subtypes impose different requirements for transformation and metastatic activity in a murine model.Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma.Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation.Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells.Exenteration and Custom Implant Brachytherapy as a Treatment for Recurrent Primary Extraskeletal Orbital Ewing Sarcoma.Pathology of Ewing's sarcoma/PNET: Current opinion and emerging concepts.Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects.Anchorage-independent multi-cellular spheroids as an in vitro model of growth signaling in Ewing tumors.Population-based genetic alterations in Ewing's tumors from Japanese and European Caucasian patients.The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers.Cytokeratin-positive meningeal peripheral PNET/Ewing's sarcoma of the cervical spinal cord: diagnostic value of genetic analysis.
P2860
Q28535586-6B883819-6644-410D-8E06-66D23728B8D7Q30990686-553B6F38-FFF5-422A-80A7-447DB3AE5324Q33813608-68DB2027-D166-4F76-9059-DFEF3BF08C79Q34032697-EDBA3465-7C7B-4A49-9515-36D49A28F862Q34317033-D4B053DE-F689-4334-A813-27566A74539DQ34683782-623684B8-DC58-4168-9206-E76211972D9CQ35013284-1F310E61-9E6D-4E8C-AC9E-EACA0BD3CB0DQ35057457-8499AA80-A4DD-4C82-BD43-53810E6FD72BQ35183100-271A9A30-727A-4856-882D-4779FB68D1C8Q35930254-F713B681-A39E-498F-9B93-0845BF75859BQ35957998-7193CD81-B854-4379-841F-7897F6D372EDQ36170917-C9E72FB1-A815-4D8F-B7C0-167FAE564378Q36294108-5E64DED6-C15E-441A-86FA-BB51AD0B00EDQ36585123-6FE963B5-199A-4CC3-BAEB-0F7A49B5BF66Q36803632-0C449F53-EC8D-4E09-8F75-00445C3A8FD9Q36806186-556B12FE-757F-43F2-89A2-EFC07A628B8CQ37134450-ACA32341-B367-4DA8-9577-61C662293F79Q37300040-26B887CB-280A-4A97-8711-8FEA8F34E558Q37348822-6D5A5F43-51A3-4BBB-8FC5-E33E24B197F9Q37370052-3F5471A7-1FBE-4FCB-9FC1-32992FFFC0CDQ37512587-550D400F-6B93-48E0-A6C3-4DF95ECAFA76Q38083655-A3BD614D-A1FE-423F-816C-38FCBCE56E8EQ38168996-F5D71F11-3B36-4DCD-BB5F-069733F42532Q38289833-B1CE077A-D5C6-4638-942B-6A46931DA0B7Q38397179-00D89D00-1E04-4A2B-91AF-82BD05A57088Q39052909-2592A5F8-2D5F-4BE9-A914-7DD6406CC31BQ39215732-0F8134C8-A506-4710-A9EC-9A9FFBD398D8Q39817075-F8D61A85-07F8-455E-8528-7DD0E377D5CDQ40015224-E22BE85C-8286-45EE-922E-5C725A895F3DQ40142173-65FDF756-818F-46FF-B1C3-E5B9559EDB24Q40298751-8A25F97B-4001-46D9-A264-4BE8CE279E69Q40606312-17249FB7-361D-47E2-91D3-567CDC0EF8BAQ40744495-5AAFB12E-5FF4-48E7-8F28-806F12015ECFQ41034886-54E215CD-C008-4FAF-82A0-BA06B019F143Q41847093-FD2E21DC-B7E4-4540-84C3-6946ABDB9871Q42453605-32998BEA-C50E-4051-AE0C-71357E7C2231Q43861826-91751002-6823-413C-9181-7561585F21FBQ46421700-D1F6CAE5-0596-4EAB-B843-E154A30E22A3Q46971533-89343219-7EE4-412E-90E5-895CEFA3AC80Q50485816-AAEABE1D-7088-439E-984F-B650539A25B1
P2860
Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma.
@ast
Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma.
@en
type
label
Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma.
@ast
Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma.
@en
prefLabel
Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma.
@ast
Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma.
@en
P2093
P2860
P1476
Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma.
@en
P2093
C R Antonescu
E de Alava
F J Pardo-Mindán
P2860
P304
P356
10.1016/S0002-9440(10)64953-X
P407
P577
2000-03-01T00:00:00Z